NCT00967096View on ClinicalTrials.gov

Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
MalignancyBone Marrow Transplantation
Interventions
DRUG

Rifaximin

Rifaximin for Bone marrow transplant patients

Trial Locations (2)

30322

Children's Healthcare of Atlanta, Atlanta

Emory University, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT00967096 - Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD) | Biotech Hunter | Biotech Hunter